published in Nature Methods in 2008.4
This notion exactly describes the intention of the third period, which I call “the
period of quality,” and which may relate
to the years between 2010 and 2030.
As a result of improved, precise imaging
technologies, direct analysis of the effects
of the device and related therapies is feasible. Magnetic resonance tomography and
related electromagnetic techniques, combined with considerable improvement in
the reduction of the signal-to-noise ratio,
allow for the application of noninvasive
sensors and thus a comfortable analysis of
patient data.
Therapies dedicated to the specific
and individual pathological condition of
patients are currently in development.
Patients with chronic diseases such as
diabetes, chronic obstructive pulmonary
disease and uraemia and those with cardiovascular problems will profit.
Medical devices of this period will be
characterised increasingly by a “systems
pies of the future and, thus, provide a
quantum leap beyond the current applica-
tion of medtech components or products
(Figure 2). 1
approach” that takes into account the
effects of polymers and biomaterials and
their active or inactive surface properties at the nano-level. Synergistic effects
between administered drugs and polymer
properties and the specific conditions of
device applications also will play a role.
These aspects will be accompanied by
new therapy standards that may facilitate
the application of complex devices and
consequently lead to reduced morbidity
and mortality of patients whilst maintaining a reasonable quality of life for them.
The expected demographic changes,
which will lead to increasing numbers of
elderly people in the population (
including their higher morbidity), will require
medical devices that offer individualised
therapies. System solutions for medical
devices, which incorporate feedback loops
between analytical sensors and adaptable
therapy parameters, as well as noninvasive
sensors based on electromagnetic effects
will be the basis for individualised thera-
NIBP - the safer, faster, more comfortable way to measure blood pressure M3600 NIBP Module (shown without cover) The Omron® M3600 is a self-contained Non-Invasive Blood Pressure (NIBP) module that combines the hardware and software necessary to perform complete blood pressure measurements. The new M3600 takes measurements from adults, children or newborns, utilising the non-invasive oscillometric method, while providing high accuracy with greater patient comfort and faster measurement speeds. This professional OEM NIBP device integration module, features:
References
1. R. Dobson, “Advances in Medical Technology
Account for a Third of the Reduction in Road
Traffic Deaths, British Medical Journal, 326,
1004 (2003).
2. D.F. Williams, “Definitions in Biomaterials,”
Proc. Consensus Conference, European Society
for Biomaterials. Chester, UK, Elsevier Science
Publishers, Amsterdam, 72 (1987).
3. H. Jennissen, “On the Definition of
Biomaterials,” Biomaterialien, 11 (S1), 110
(2010).
4. M. Brameshuber and G. Schütz, “How the
Sum of its Parts Gets Greater than the Whole,”
Nature Methods, 5, 133-146 (2008).
Professor Dr Jörg Vienken
is Vice President, BioSciences,
Fresenius Medical Care Deutschland GmbH,
Else-Kröner-Straße 1, D-61352 Bad Homburg
tel. + 49 6172 609 2463
e-mail: joerg.vienken@fmc-ag.com
www.fmc-ag.com
; Hospital Grade Design – dual transducers and dual CPU processors. Complies with ANSI/AAMI SPIO:2002
; Smart Inflation™ – automatically determines patient-specific pressures and controls inflation rate accordingly
; Dynamic Linear Deflation – faster measurements without affecting accuracy
; Support – Omron’s 30 year expertise in BP measurement
Omron - providing safe, high technology products to Medical OEMs.
www.components.omron.eu
emdt.co.uk European Medical Device Technology
June 2010 | 37
